Pharma Blog Watch

Tough Luck for Pharmacyclics (Pharmalot)
In his blog, Ed Silverman writes about Pharmacyclics' announcement this week that its new drug application for the cancer drug Xcytrin was found to be incomplete and rejected by the FDA, causing the firm's stock to dive.

But the company "is in relatively good financial shape," and, according to an analyst Silverman cites, "This is not the end for Xcytrin."

"Such optimism could only be reserved for a struggling biotech, no?"